315 related articles for article (PubMed ID: 33246930)
21. Evaluation of Out-of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes and Cardiovascular Disease.
Luo J; Feldman R; Callaway Kim K; Rothenberger S; Korytkowski M; Hernandez I; Gellad WF
JAMA Netw Open; 2023 Jun; 6(6):e2317886. PubMed ID: 37307000
[TBL] [Abstract][Full Text] [Related]
22. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Fralick M; Chen SK; Patorno E; Kim SC
Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
[TBL] [Abstract][Full Text] [Related]
23. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
[TBL] [Abstract][Full Text] [Related]
24. Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case-control study.
Saito T; Nojiri S; Kasai T; Hiratsuka Y; Ishijima M; Daida H
Geriatr Gerontol Int; 2023 Jun; 23(6):418-425. PubMed ID: 37139826
[TBL] [Abstract][Full Text] [Related]
25. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study.
Chen HY; Huang JY; Siao WZ; Jong GP
Cardiovasc Diabetol; 2020 Jun; 19(1):73. PubMed ID: 32503541
[TBL] [Abstract][Full Text] [Related]
26. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
27. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
28. Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.
Nadkarni GN; Ferrandino R; Chang A; Surapaneni A; Chauhan K; Poojary P; Saha A; Ferket B; Grams ME; Coca SG
Diabetes Care; 2017 Nov; 40(11):1479-1485. PubMed ID: 28827404
[TBL] [Abstract][Full Text] [Related]
29. Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan.
Mizutani G; Horii T; Oikawa Y; Atsuda K; Shimada A
J Diabetes Investig; 2022 Dec; 13(12):2000-2009. PubMed ID: 36124433
[TBL] [Abstract][Full Text] [Related]
30. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.
Chen Z; Li G
Clin Drug Investig; 2019 Jun; 39(6):521-531. PubMed ID: 31041606
[TBL] [Abstract][Full Text] [Related]
31. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors.
Dave CV; Schneeweiss S; Patorno E
Diabetes Obes Metab; 2019 Feb; 21(2):434-438. PubMed ID: 30207042
[TBL] [Abstract][Full Text] [Related]
32. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study.
Pasternak B; Ueda P; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Wintzell V; Melbye M; Svanström H
BMJ; 2019 Aug; 366():l4772. PubMed ID: 31467044
[TBL] [Abstract][Full Text] [Related]
33. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
34. Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.
Su YC; Shao SC; Lai EC; Lee CN; Hung MJ; Lai CC; Hsu SM; Hung JH
Diabetes Obes Metab; 2021 Sep; 23(9):2067-2076. PubMed ID: 34047442
[TBL] [Abstract][Full Text] [Related]
35. The association between sodium-glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study.
Siao WZ; Lin TK; Huang JY; Tsai CF; Jong GP
Diab Vasc Dis Res; 2022; 19(3):14791641221098168. PubMed ID: 35549730
[TBL] [Abstract][Full Text] [Related]
36. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
[TBL] [Abstract][Full Text] [Related]
38. SGLT2 inhibitor treatment is not associated with an increased risk of osteoporotic fractures when compared to GLP-1 receptor agonists: A nationwide cohort study.
Al-Mashhadi ZK; Viggers R; Starup-Linde J; Vestergaard P; Gregersen S
Front Endocrinol (Lausanne); 2022; 13():861422. PubMed ID: 36060970
[TBL] [Abstract][Full Text] [Related]
39. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.
Ito H; Shinozaki M; Nishio S; Abe M
Expert Opin Pharmacother; 2016 Oct; 17(15):2073-84. PubMed ID: 27592508
[TBL] [Abstract][Full Text] [Related]
40. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]